Clinical Trial Update: Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the effects of JNJ-54861911 on amyloid-beta processing in cerebrospinal fluid and plasma in Japanese participants asymptomatic at ris…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• JNJ-54861911

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED